South Korea · Delayed Price · Currency is KRW GC Biopharma Statistics
Total Valuation
GC Biopharma has a market cap or net worth of KRW 1.40 trillion. The enterprise value is 2.38 trillion.
| Market Cap | 1.40T |
| Enterprise Value | 2.38T |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
GC Biopharma has 11.41 million shares outstanding.
| Current Share Class | 11.41M |
| Shares Outstanding | 11.41M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.95% |
| Owned by Institutions (%) | 14.18% |
| Float | 5.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 5.62 |
| PS Ratio | 0.71 |
| PB Ratio | 1.06 |
| P/TBV Ratio | 1.55 |
| P/FCF Ratio | 15.96 |
| P/OCF Ratio | 7.60 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.13, with an EV/FCF ratio of 27.16.
| EV / Earnings | n/a |
| EV / Sales | 1.21 |
| EV / EBITDA | 14.13 |
| EV / EBIT | 28.69 |
| EV / FCF | 27.16 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.30 |
| Quick Ratio | 0.40 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 7.07 |
| Debt / FCF | 10.70 |
| Interest Coverage | 0.93 |
Financial Efficiency
Return on equity (ROE) is -4.54% and return on invested capital (ROIC) is 2.15%.
| Return on Equity (ROE) | -4.54% |
| Return on Assets (ROA) | 1.00% |
| Return on Invested Capital (ROIC) | 2.15% |
| Return on Capital Employed (ROCE) | 2.62% |
| Weighted Average Cost of Capital (WACC) | 6.60% |
| Revenue Per Employee | 930.34M |
| Profits Per Employee | -23.64M |
| Employee Count | 2,111 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.63 |
Taxes
In the past 12 months, GC Biopharma has paid 5.26 billion in taxes.
| Income Tax | 5.26B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.88% in the last 52 weeks. The beta is 0.71, so GC Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -7.88% |
| 50-Day Moving Average | 124,330.00 |
| 200-Day Moving Average | 141,088.00 |
| Relative Strength Index (RSI) | 42.26 |
| Average Volume (20 Days) | 18,689 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GC Biopharma had revenue of KRW 1.96 trillion and -49.90 billion in losses. Loss per share was -4,372.28.
| Revenue | 1.96T |
| Gross Profit | 517.00B |
| Operating Income | 47.28B |
| Pretax Income | -58.19B |
| Net Income | -49.90B |
| EBITDA | 132.85B |
| EBIT | 47.28B |
| Loss Per Share | -4,372.28 |
Balance Sheet
The company has 44.66 billion in cash and 938.85 billion in debt, with a net cash position of -894.19 billion or -78,347.54 per share.
| Cash & Cash Equivalents | 44.66B |
| Total Debt | 938.85B |
| Net Cash | -894.19B |
| Net Cash Per Share | -78,347.54 |
| Equity (Book Value) | 1.33T |
| Book Value Per Share | 108,356.51 |
| Working Capital | 305.55B |
Cash Flow
In the last 12 months, operating cash flow was 184.28 billion and capital expenditures -96.52 billion, giving a free cash flow of 87.77 billion.
| Operating Cash Flow | 184.28B |
| Capital Expenditures | -96.52B |
| Depreciation & Amortization | 85.57B |
| Net Borrowing | -117.13B |
| Free Cash Flow | 87.77B |
| FCF Per Share | 7,690.02 |
Margins
Gross margin is 26.32%, with operating and profit margins of 2.41% and -2.54%.
| Gross Margin | 26.32% |
| Operating Margin | 2.41% |
| Pretax Margin | -2.96% |
| Profit Margin | -2.54% |
| EBITDA Margin | 6.76% |
| EBIT Margin | 2.41% |
| FCF Margin | 4.47% |
Dividends & Yields
This stock pays an annual dividend of 1,500.00, which amounts to a dividend yield of 1.22%.
| Dividend Per Share | 1,500.00 |
| Dividend Yield | 1.22% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 1.18% |
| Earnings Yield | -3.56% |
| FCF Yield | 6.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for GC Biopharma is 191,625.00, which is 56.17% higher than the current price. The consensus rating is "Buy".
| Price Target | 191,625.00 |
| Price Target Difference | 56.17% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 4.23% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 7, 2013. It was a forward split with a ratio of 1.05.
| Last Split Date | Jun 7, 2013 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
GC Biopharma has an Altman Z-Score of 1.93 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.93 |
| Piotroski F-Score | 5 |